No. 18: Zimmer Biomet
Warsaw, Ind.
2018 revenues: $7,932,900,000
R&D spend: $391,700,000
Employees: 19,000
Revenues/employee: $417,521
Fiscal year ending: Dec. 31, 2018
Last year’s rank: 17
Key Personnel:
Bryan Hanson, president & CEO: Aure Bruneau, president, spine, CMF, thoracic & surgery-assisting technology; Didier Deltort, president, EMEA; Rachel Ellingson, SVP, strategy; David Kunz, SVP, global quality & regulatory affairs; Cole Lannum, SVP, IR; Angela Main, SVP, global chief compliance officer & associate GC, Asia Pacific; Pedro Malha, president, dental; Chad Phipps, SVP, GC & secretary; Pamela Puryear, SVP, chief HR officer; Zeeshan Tariq, VP & CIO; Ivan Tornos, group president, orthopedics; Kenneth Tripp, SVP, global operations & logistics; Suketu Upadhyay, EVP & CFO; Sang Yi, president, Asia Pacific
Description:
Zimmer Biomet (NYSE:ZBH) in July raised its 2019 outlook after reporting Q2 results that beat Wall Street expectations. The orthopedic device giant reported that an ongoing turnaround is six months ahead of schedule. The company in 2018 won FDA clearance for its Persona revision knee implant and its customized components to match each patient’s anatomy. Early this year, Zimmer Biomet won clearance for the Rosa Knee robot-assisted total knee replacement surgery platform, followed by clearance for the Rosa One robotic spine system. Zimmer Biomet is also touting Mymobility, its patient care management app for the Apple Watch and iPhone. – CN